<DOC>
	<DOCNO>NCT02804386</DOCNO>
	<brief_summary>Title Efficacy Safety Zoval ( Sofosbuvir ) Ribavirin without Interferon among Pakistani Population : A real life trial Hepatitis Eradication Accuracy Trial Sofosbuvir ( HEATS ) Study Design Endpoint Classification : Safety/Efficacy Study Intervention Model : Treatment agent ( non-interventional observational study ) : Real life clinical practice study Masking : Open Label Primary Purpose : Treatment Duration Around 12 Months Study Centre Multi centric Study</brief_summary>
	<brief_title>Efficacy Safety Zoval ( Sofosbuvir ) Ribavirin With Without Interferon</brief_title>
	<detailed_description>Indication Chronic Hepatitis C Virus ( HCV ) infection ( serum HCV RNA level , &gt; 10,000 IU per milliliter ) without cirrhosis Primary Objective Proportion participant sustain virologic response 12/24 week discontinuation therapy ( SVR 12 24 week ) [ Time Frame : Post-treatment Week 12/24 ] [ Designated safety issue : No ] SVR 12/24 define HCV RNA &lt; low limit quantification ( LLOQ ; ie , &lt; 15 IU/mL ) 12/24 week follow last dose study medication . Secondary Objective Proportion participant experience viral breakthrough [ Time Frame : Up 12 24 week ] [ Designated safety issue : No ] Viral breakthrough define HCV RNA ≥ low limit quantification ( LLOQ ) previously HCV RNA &lt; LLOQ receive treatment , confirm 2 consecutive value ( second confirmation value could post treatment ) , last available on-treatment measurement subsequent follow-up value . - Proportion participant experience viral relapse [ Time Frame : Up Post treatment Week 12 24 ] [ Designated safety issue : No ] Viral relapse define HCV RNA ≥ LLOQ post-treatment period achieve HCV RNA &lt; LLOQ end treatment , confirm 2 consecutive value last available post treatment measurement . - Proportion participant Early Virological Response 4 week start therapy ( EVR4 ) [ Time Frame : Treatment Week 4 ] [ Designated safety issue : No ] - SVR 12/24 define HCV RNA &lt; low limit quantification ( LLOQ ; ie , &lt; 15 IU/mL ) 12/24 week follow last dose study medication.Proportion HCV RNA within 12 24 week change baseline HCV RNA ( log10 IU/mL ) [ Time Frame : Up 12 24 week ] [ Designated safety issue : No ] - Proportion participant experience adverse event ( AE ) lead permanent discontinuation study medication [ Time Frame : Baseline Week 12 24 ] [ Designated safety issue : No ] Number Subjects 5000 patient Dosing - Sofosbuvir 400 mg tablet take daily orally - Ribavirin twice daily orally - 1000 mg patient body weight &lt; 75 kg - 1200 mg weight &gt; 75 kg - Interferon 12 24 week Drug duration Duration combination depend upon discretion Principal investigator . Proposed Duration Genotype : Inclusion criterion • Men woman , 18 year age old , - Treatment -Naïve respond previous therapy - HCV Relapse - Patient HCV wait transplant , bridge transplant - Cirrhosis - Not previously enrol trial/study Sofosbuvir Exclusion criterion Not give informed consent Pregnancy</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Men woman , 18 year age old , Treatment Naïve respond previous therapy Cirrhosis Not previously enrol trial Sofosbuvir Not give informed consent Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HCV</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>EVR</keyword>
	<keyword>SVR</keyword>
</DOC>